ValuEngine upgraded shares of Histogenics (NASDAQ:HSGX) from a strong sell rating to a sell rating in a research note issued to investors on Friday morning.
Several other equities research analysts have also commented on HSGX. Zacks Investment Research lowered Histogenics from a buy rating to a hold rating in a research note on Monday, October 16th. HC Wainwright restated a buy rating and issued a $3.50 price objective on shares of Histogenics in a research note on Thursday, November 2nd. Finally, Canaccord Genuity restated a buy rating and issued a $4.00 price objective on shares of Histogenics in a research note on Thursday, December 21st.
Shares of Histogenics (NASDAQ:HSGX) traded up $0.05 on Friday, reaching $2.84. 205,021 shares of the company’s stock were exchanged, compared to its average volume of 223,361. The stock has a market cap of $69.59, a price-to-earnings ratio of -12.91 and a beta of 1.88. Histogenics has a 1-year low of $1.50 and a 1-year high of $3.13.
WARNING: “Histogenics (HSGX) Upgraded at ValuEngine” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2018/02/03/histogenics-hsgx-upgraded-at-valuengine.html.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.